Phylogica enters into research and licensing agreement with Genentech

Published: 6-Jan-2015
Research & Development

Perth, Australia-based company will receive an upfront payment of US$500,000


Phylogica, an Australian peptide drug discovery company, has extended its collaboration with Genentech, the biotechnology division of Roche Group, by entering into a research and licensing agreement to discover novel antibiotics.

Under the terms of the agreement, Perth-based Phylogica will receive an upfront payment of US$500,000. In addition, the company is eligible to receive research, development, and commercialisation milestone payments totalling up to US$142m.

The companies signed their first research agreement in August 2014.

Phylogica will use its Phylome drug discovery platform, including its proprietary cell penetrating peptide discovery technology to identify Phylomer peptides suitable for further evaluation.

Phylogica’s CEO Dr Richard Hopkins said: 'We are delighted to continue building upon on the success of our initial collaboration with Genentech. This alliance has the potential to address an unmet need for novel antimicrobials to treat bacterial infections, including drug-resistant superbugs.'

  • Companies:
  • Phylogica
  • Genentech
See more

You may also like

Research & Development

Scenic Biotech enters into genetic modifier collaboration with Genentech

Read more
Multi-year strategic collaboration in target discovery and therapeutic development based on Scenic Biotech’s disease modifying approach

Trending Articles

  1. Thermo Fisher Scientific reveals MagMax Sequential DNA/RNA Kit to advance blood cancer research The kit combines DNA and RNA isolation chemistries into a single kit, simplifying sample extraction for a broad range of downstream molecular applications
  2. Asahi Kasei Pharma grows its global portfolio with anti-CX3CR1 license The licensing deal with Chiome enhances its open innovation platform
  3. Medac and chiron develop organ-on chip tech for animal free drug testing The companies aim to develop an animal-free pharmaceutical testing method that utilises organ-on chip technology, and will be used in rheumatoid arthritis drug testing
  4. How iPSCs can bridge the translational gap in neuroscience Affecting more than one in three people, neurological disorders have a vast impact on global health while exacting a tremendous cost, reports Dr Max Mirza, Vice President of Neuroscience Drug Discovery at Sygnature Discovery
  5. RCPE and InSilicoTrials to digitalise and accelerate the development of pharmaceutical manufacturing processes RCPE and InSilicoTrials have agreed to an exclusive partnership to commercialise the XPS simulation software. Specifically developed for pharmaceutical applications, XPS allows companies to assess their process configurations in unprecedented detail and explore the decision space without time- and labour-intensive experiments

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Research & Development

Scenic Biotech enters into genetic modifier collaboration with Genentech

Multi-year strategic collaboration in target discovery and therapeutic development based on Scenic Biotech’s disease modifying approach
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Optimising scale-up with flow process technologies

Speed of synthesis is of the essence when medicinal chemists invent new molecules, reports Sarah Houlton
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

ADCs: a more effective, less harmful, targeted approach

Antibody-drug conjugates could hold the key to delivering highly potent anticancer drugs more accurately to the tumour site with less damage to healthy cells
Regulatory

Rheumatoid arthritis – sarilumab

Not all patients respond well to or tolerate TNF-alpha inhibitors, and an alternative strategy might be to treat with a drug against the interleukin-6 receptor alpha
Research & Development

Almac Discovery in ubiquitin specific protease collaboration with Genentech

Almac Discovery’s novel, potent and selective small molecule inhibitors will be the starting point for a two-year joint research programme
Research & Development

Phylogica signs deal with UK biotech to identify and develop cancer drugs

Takes a 7.5% stake in PhoreMost, based in Cambridge
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

Reimbursment issues hinder future development of personal therapies

The development of more targeted therapies is moving apace, but are the payers prepared for it? Dr Sarah Houlton looks at the progress of personalised medicines
Subscribe now